Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in ...

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...